Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Assets Average (2016 - 2025)

Historic Assets Average for CytomX Therapeutics (CTMX) over the last 11 years, with Q3 2025 value amounting to $166.7 million.

  • CytomX Therapeutics' Assets Average rose 1177.43% to $166.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.7 million, marking a year-over-year increase of 1177.43%. This contributed to the annual value of $161.2 million for FY2024, which is 3033.57% down from last year.
  • Per CytomX Therapeutics' latest filing, its Assets Average stood at $166.7 million for Q3 2025, which was up 1177.43% from $136.8 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Assets Average registered a high of $418.3 million during Q2 2021, and its lowest value of $109.5 million during Q1 2025.
  • In the last 5 years, CytomX Therapeutics' Assets Average had a median value of $221.9 million in 2023 and averaged $241.8 million.
  • The largest annual percentage gain for CytomX Therapeutics' Assets Average in the last 5 years was 1177.43% (2025), contrasted with its biggest fall of 4332.68% (2025).
  • Over the past 5 years, CytomX Therapeutics' Assets Average (Quarter) stood at $355.3 million in 2021, then crashed by 31.42% to $243.7 million in 2022, then dropped by 13.22% to $211.5 million in 2023, then plummeted by 38.64% to $129.8 million in 2024, then rose by 28.44% to $166.7 million in 2025.
  • Its Assets Average was $166.7 million in Q3 2025, compared to $136.8 million in Q2 2025 and $109.5 million in Q1 2025.